drugset
drugset / Trial / NCT01642082

Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer

NCT01642082 ↗

Phase 2 Completed 28 enrolled Gynecologic Oncology Group National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well dalantercept works in treating patients with endometrial cancer that has come back or is persistent. Dalantercept may stop the growth of endometrial cancer by blocking blood flow to the tumor.

Timeline

Start
2012-09
Primary completion
2016-01
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Dalantercept Protein / enzyme biologic — Subcutaneous

Indications

endometrial clear cell adenocarcinoma endometrial mixed adenocarcinoma endometrial mucinous adenocarcinoma endometrial serous adenocarcinoma endometrial squamous cell carcinoma endometrial transitional cell carcinoma endometrial undifferentiated carcinoma